Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:9953 |
Name | acute biphenotypic leukemia |
Definition | An acute leukemia that is characterized by the occurrence of more than one type of leukemia at the same time resulting from either the occurrence of blasts which coexpress myeloid and T or B lineage antigens or concurrent B and T lineage antigens. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute biphenotypic leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
NRAS Q61R | Trametinib | acute biphenotypic leukemia | no benefit | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02091245 | Phase I | Selinexor | Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | Active, not recruiting | USA | 0 |
NCT03326921 | Phase I | Fludarabine HA-1 TCR T cells | HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | Suspended | USA | 0 |
NCT04501614 | Phase Ib/II | Ponatinib | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Recruiting | USA | ITA | GBR | FRA | ESP | AUS | 9 |
NCT04827745 | Phase II | Blinatumomab | Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL | Active, not recruiting | USA | 0 |
NCT04872478 | Phase I | MRX-2843 | Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL | Recruiting | USA | 0 |
NCT04964518 | Phase I | APG-2575 + Azacitidine | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | Recruiting | USA | AUS | 0 |
NCT05038644 | Phase I | XmAb18968 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT05146739 | Phase I | Cytarabine + Fludarabine + Uproleselan | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane | Recruiting | USA | 0 |
NCT05292664 | Phase I | Azacitidine + Cytarabine + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax Calaspargase pegol-mknl + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax + Vincristine Sulfate Azacitidine + Venetoclax | Venetoclax Basket Trial for High Risk Hematologic Malignancies | Recruiting | USA | 0 |
NCT05326516 | Phase I | Revumenib | A Study of SNDX-5613 in Combination With Chemotherapy in Participants With Leukemia | Recruiting | USA | 0 |
NCT05360160 | Phase Ib/II | Decitabine and Cedazuridine Revumenib Venetoclax | A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) | Recruiting | USA | 0 |
NCT05476770 | Phase I | Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Tagraxofusp-erzs + Vincristine Sulfate Azacitidine + Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Fludarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Recruiting | USA | AUS | 0 |
NCT05848687 | Phase Ib/II | Bortezomib Dexamethasone Blinatumomab Vorinostat Mercaptopurine Pegaspargase Methotrexate Ziftomenib Mitoxantrone | TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Not yet recruiting | USA | 0 |
NCT05918692 | Phase I | BMF-500 | A Phase 1, Study of BMF-500 in Adults With Acute Leukemia | Recruiting | USA | 0 |